Cartesian Aurora What is the AURORA Study? The aim of the AURORA Study is to assess the safety and effectiveness of an mRNA CAR T-cell therapy, known as Descartes-08, as a potential approach to treat generalized myasthenia gravis. Myasthenia gravis is an autoimmune disease, which means that the immune system mistakenly produces antibodies (proteins that […]
Novartis “Relieve” We are assessing the effectiveness and safety of remibrutinib, an investigational medicine being developed for people who have generalized Myasthenia Gravis (gMG). Click here for More Information Inclusion Criteria: – Have a confirmed, documented diagnosis of gMG: either positive for AChR+ antibody or MuSK+ antibody, or seronegative for both AChR and MuSK antibodies
Novartis “Relieve” Read More »
ArgenX Empassion The Empassion study is designed to assess how safe and effective an investigational study drug, empasiprubart, is compared to intravenous immunoglobulin (IVIg) as a possible treatment for adults living with multifocal motor neuropathy (MMN). The clinical study is looking to enroll up to 100 participants across the world. Enrolled participants will be asked
Supernus RENAISSANCE 2 Please see below for Epilepsy Research Opportunity. For more information please contact: Jacara WashingtonClinical Research CoordinatorP: 716-961-9220E: jawashington@dentinstitute.com
Supernus RENAISSANCE 2 Read More »
Sanofi VITALIZE A Phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy. The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will
BMS TARGET-TAU This study is being done to learn more about the safety and efficacy of an investigational medication called BMS-986446 in adults aged 50-80 years with mild cognitive impairment due to Alzheimer’s disease, or mild Alzheimer’s dementia. Inclusion Criteria: Are 50-80 years old Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease,
TG ENABLE The purpose of this study is to evaluate safety, effectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting. Inclusion Criteria: Participants with a confirmed Multiple Sclerosis (MS) diagnosis who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion. For more
EVIDERA EVA-38569-03 This is a cognitive interview study to evaluate Phase 2 Trial Anchors in Patients with Parkinson’s Disease. What to Expect This study involves in-depth interviews with adults who have been diagnosed with PD who meet specific criteria. For more information, contact Heather Macnamara at hmacnamara@dentinstitute.com or 716-819-4117
EVIDERA EVA-38569-03 Read More »
TEVA IMPACT TD Registry (Tardive Dyskinesia) The purpose of this study is to uncover how tardive dyskinesia (TD) develops over time and its impact on individuals. Inclusion Criteria: Patients who are newly initiating deutetrabenazine as part of routine clinical practice. What to Expect As part of your usual care, you will complete questionnaires and visit
Alzheimer’s National Registry for Treatment and Diagnostics(ALZ-NET) (Mild Cognitive Impairment and Alzheimer’s Disease) ALZ-NET collects clinical and safety data about patients being evaluated for memory concerns or receiving new FDA-approved treatments for Alzheimer’s disease, including drugs/medications and devices, and tracks the long-term health outcomes associated with their use in real-world settings. ALZ-NET is a voluntary
